Evaluation of Prescription Patterns of Antipsychotics in Schizophrenia Patients—A Single-Center Prospective Study

Inappropriate prescription patterns and polypharmacy are critical challenges facing the optimal management of schizophrenia patients, especially in regard to patient safety. <b>Background/Objectives</b>: The purpose of this study was to examine the relationship between patient safety and the existence of incorrect prescription patterns and/or polypharmacy in the medications prescribed to individuals with schizophrenia. This issue is addressed in a broad context, highlighting the purpose of this study. <b>Methods</b>: A cross-sectional study was adopted, involving a prospective analysis of the prescriptions of schizophrenia patients receiving treatment. Prescription patterns deemed inappropriate were evaluated based on evidence-based guidelines. Antipsychotic maximum allowable daily doses were calculated using the British National Formulary Maximum Daily Dose (BNFmax), an online tool. Patient safety outcomes were assessed using the Glasgow Antipsychotic Side-effect Scale (GASS). <b>Results</b>: A total of 198 patients diagnosed with schizophrenia and receiving treatment consented to participate in the GASS survey. A total of 116 (58.6%) males participated. The mean age of patients was 40.1 (±12.7). Thirty-one (66.2%) reported mild side effects, while 67 (33.8%) reported moderate side effects. Polypharmacy was detected in 103 (52%) patients' prescriptions. The correlation between GASS and BNFmax was positive and statistically significant (<i>p</i> < 0.001). The elevation in GASS score was associated with polypharmacy prescriptions (OR 3.21; 95% CI 1.64-6.29), the presence of first-generation antipsychotics (FGAP) (OR 2.79; 95% CI 0.236-5.951), any combination of antipsychotics containing haloperidol (OR 3.22; 95% CI 1.11-9.32), and olanzapine (OR 3.46; 95% CI 1.36-8.79). <b>Conclusions</b>: The safety of patients with schizophrenia has been proven to be impacted by the improper use of psychotropic drugs. Following evidence-based guidelines is a cornerstone to ensuring optimal, effective, and safe patient treatment plans.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-04-24
DOI
https://doi.org/10.3390/jcm14092941
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of Prescription Patterns of Antipsychotics in Schizophrenia Patients—A Single-Center Prospective Study

Abdulaziz Almulhim, Ahmed Mohamed, Abdulrahman A Alnijadi, Farhan M. Aziz et al.
Journal of Clinical Medicine
Schizophrenia research and treatment
article

Evaluation of Prescription Patterns of Antipsychotics in Schizophrenia Patients—A Single-Center Prospective Study

Abdulaziz Almulhim, Ahmed Mohamed, Abdulrahman A Alnijadi, Farhan M. Aziz, M. Almutairi, Khuloud Khaled Alajmi, Ahmed Abdullah Al-Mudhaffar
article en

Abstract

Inappropriate prescription patterns and polypharmacy are critical challenges facing the optimal management of schizophrenia patients, especially in regard to patient safety. <b>Background/Objectives</b>: The purpose of this study was to examine the relationship between patient safety and the existence of incorrect prescription patterns and/or polypharmacy in the medications prescribed to individuals with schizophrenia. This issue is addressed in a broad context, highlighting the purpose of this study. <b>Methods</b>: A cross-sectional study was adopted, involving a prospective analysis of the prescriptions of schizophrenia patients receiving treatment. Prescription patterns deemed inappropriate were evaluated based on evidence-based guidelines. Antipsychotic maximum allowable daily doses were calculated using the British National Formulary Maximum Daily Dose (BNFmax), an online tool. Patient safety outcomes were assessed using the Glasgow Antipsychotic Side-effect Scale (GASS). <b>Results</b>: A total of 198 patients diagnosed with schizophrenia and receiving treatment consented to participate in the GASS survey. A total of 116 (58.6%) males participated. The mean age of patients was 40.1 (±12.7). Thirty-one (66.2%) reported mild side effects, while 67 (33.8%) reported moderate side effects. Polypharmacy was detected in 103 (52%) patients' prescriptions. The correlation between GASS and BNFmax was positive and statistically significant (<i>p</i> < 0.001). The elevation in GASS score was associated with polypharmacy prescriptions (OR 3.21; 95% CI 1.64-6.29), the presence of first-generation antipsychotics (FGAP) (OR 2.79; 95% CI 0.236-5.951), any combination of antipsychotics containing haloperidol (OR 3.22; 95% CI 1.11-9.32), and olanzapine (OR 3.46; 95% CI 1.36-8.79). <b>Conclusions</b>: The safety of patients with schizophrenia has been proven to be impacted by the improper use of psychotropic drugs. Following evidence-based guidelines is a cornerstone to ensuring optimal, effective, and safe patient treatment plans.

Journal of Clinical MedicineVol. 14(9)
Universiti Sains Malaysia (MY), King Faisal University (SA)
Good health and well-being
Openalex Percentile: Top 89%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.